Smitha Krishnamurthi: Thrilled to Open Solstice Oncology’s Phase II Trial of Neoadjuvant Immunotherapy in MSS Colon Cancer
Smitha Krishnamurthi/LinkedIn

Smitha Krishnamurthi: Thrilled to Open Solstice Oncology’s Phase II Trial of Neoadjuvant Immunotherapy in MSS Colon Cancer

Smitha Krishnamurthi, Staff Physician at Cleveland Clinic, shared on LinkedIn:

“Thrilled to have opened Solstice Oncology‘s phase 2 trial of neoadjuvant porustobart and pembrolizumab for patients with MSS colon cancer! Porustobart is a second generation Fc- enhanced CTLA-4 antibody.

Truly believe neoadjuvant immunotherapy is how we will cure more patients with colorectal cancer!”

Aparna Parikh, Chief Scientist, Co-Founder, CEO at Reversing Early Recurrence, shared this post, adding:

“This study is not quite open, but on its way to being open at the MGBCI. The goal for our program has been to improve cure rates spanning the stages of disease including early stage disease.

We want to have a trial for every patient walking in the door as our good is not yet good enough.”

You can also read: UNICORN Challenges Immunotherapy Resistance in MSS Colon Cancer

Smitha Krishnamurthi: Thrilled to Open Solstice Oncology’s Phase II Trial of Neoadjuvant Immunotherapy in MSS Colon Cancer